SpringWorks Therapeutics (NASDAQ:SWTX) Earns Outperform Rating from Wedbush

SpringWorks Therapeutics (NASDAQ:SWTX)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a report issued on Thursday,RTT News reports. They presently have a $81.00 price objective on the stock. Wedbush’s price target points to a potential upside of 35.16% from the stock’s current price. Wedbush also issued estimates for SpringWorks Therapeutics’ Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at $0.23 EPS, FY2027 earnings at $3.55 EPS and FY2028 earnings at $8.09 EPS.

Several other research firms have also recently issued reports on SWTX. HC Wainwright reiterated a “buy” rating and issued a $74.00 price target on shares of SpringWorks Therapeutics in a report on Wednesday, February 12th. Evercore ISI upped their target price on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Finally, Guggenheim decreased their price target on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $71.50.

SpringWorks Therapeutics Trading Up 7.5 %

NASDAQ SWTX traded up $4.20 on Thursday, reaching $59.93. The stock had a trading volume of 5,140,295 shares, compared to its average volume of 2,724,109. SpringWorks Therapeutics has a 1 year low of $28.21 and a 1 year high of $62.00. The business has a 50 day moving average price of $40.27 and a 200 day moving average price of $37.31. The company has a market capitalization of $4.46 billion, a price-to-earnings ratio of -15.45 and a beta of 0.81.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. On average, analysts anticipate that SpringWorks Therapeutics will post -3.04 earnings per share for the current fiscal year.

Insider Buying and Selling at SpringWorks Therapeutics

In related news, CEO Saqib Islam sold 10,672 shares of SpringWorks Therapeutics stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $59.92, for a total transaction of $639,466.24. Following the sale, the chief executive officer now directly owns 1,063,953 shares in the company, valued at $63,752,063.76. This trade represents a 0.99 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Badreddin Edris sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total value of $839,400.00. Following the transaction, the chief operating officer now owns 209,600 shares of the company’s stock, valued at $8,796,912. This trade represents a 8.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 313,822 shares of company stock valued at $16,802,876 in the last ninety days. 7.61% of the stock is currently owned by company insiders.

Institutional Trading of SpringWorks Therapeutics

Several hedge funds have recently modified their holdings of the stock. Huntington National Bank boosted its stake in SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company’s stock valued at $25,000 after purchasing an additional 192 shares during the last quarter. AlphaQuest LLC boosted its stake in shares of SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after purchasing an additional 414 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in SpringWorks Therapeutics in the fourth quarter valued at $45,000. State of Wyoming raised its holdings in SpringWorks Therapeutics by 39.5% in the 4th quarter. State of Wyoming now owns 1,530 shares of the company’s stock worth $55,000 after purchasing an additional 433 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of SpringWorks Therapeutics in the 4th quarter worth about $56,000.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.